BUZZ-Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook
Reuters
Nov 06
BUZZ-Australia's Neuren Pharma at more than 2-month-low on revising royalty outlook
** Neuren PharmaceuticalsNEU.AX slips as much as 11.3% to A$17.95, lowest since August 27; among top losers on S&P/ASX 200 index .AXJO
** Biopharma co says Nasdaq-listed Acadia AACD.O narrowed FY25 U.S. net sales outlook for co's Rett syndrome medication, DAYBUE, to $385 mln–400 mln from $380 mln-405 mln
** Neuren granted exclusive worldwide licence to Acadia for development, commercialisation of DAYBUE
** Outlook revision implies FY25 U.S. royalty income for Neuren seen at A$63 mln ($41 mln)-A$66 mln vs A$62 mln-A$67 mln expected earlier
** YTD, NEU gains 49.8%
($1 = A$1.5389)
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.